IsoRay Announces Positive Peer Review Of Cesium-131 In Treatment Of Metastatic Brain Cancer

IsoRay ISR announced the publication of the first peer reviewed study showing the superior results from using IsoRay's Cesium-131 in the treatment of metastatic brain cancer.  CEO Dwight Babcock stated "We are extremely excited to have growing evidence that Cesium-131 isotope seeds continue to perform so well against aggressive cancers...".  

Metastatic, or secondary, brain tumors begin as cancer in other parts of the body.  Cancer cells may be carried to the brain through the blood or lymphatic fluid, resulting in the possibility of cancer spreading to adjacent tissues.  A metastatic brain tumor is one of the more common brain tumors found.  As the exclusive manufacture of Cesium-131, IsoRay owns the rights to one of the most significant advances in internal radiation therapy in nearly 2 decades.  

The researchers concluded their study by saying "This treatment was safe, well tolerated, and convenient for patients, resulting in a short radiation treatment course, high response rate, and minimal toxicity".  Cesium-131 is FDA cleared and holds a CE mark for international sales in seed form.  

Shares of IsoRay are trading up roughly 11 percent on Tuesday morning to $2.63